Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Discovery Labs Plunges on New Surfaxin Delay

By Pharmaceutical Processing | April 15, 2013

NEW YORK (AP) — Shares of Discovery Laboratories Inc. plunged today after the company said the launch of its respiratory drug Surfaxin will be delayed about six more months, to the fourth quarter of 2013.

Discovery Labs said the Food and Drug Administration asked it to provide more information about the way it documents Surfaxin product specifications and a new analytical chemistry method. The Warrington, Pa., company said it will respond to the FDA within two months, and the agency will have up to four months to review the new submissions. If the review is successful, Discovery Labs said it would start marketing Surfaxin during the fourth quarter.

The company’s stock declined 40 cents, or 16.7 percent, to $1.99 in midday trading.

Surfaxin is intended to prevent a condition called respiratory distress syndrome in premature infants. Respiratory distress syndrome occurs when children are born without enough pulmonary surfactant, a substance produced by the lungs that is essential for breathing. The condition is often treated with mechanical ventilation and animal-derived surfactant replacements.

The FDA approved Surfaxin in March 2012, and at the time, Discovery Labs said it would start marketing the drug during the fourth quarter of the year. But in October, the company said it had to update product specifications and one of the ways it measured the performance of Surfaxin. Discovery Labs said that would delay the launch of Surfaxin to the second quarter of 2013.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE